At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Carotenoids; Small molecules
- Mechanism of Action Free radical scavengers; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 30 Oct 1997 No-Development-Reported for Cancer in France (Unknown route)
- 30 Oct 1997 No-Development-Reported for Cancer in Greece (Unknown route)